Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

PURPOSE: Long-acting injectable (LAI) antipsychotic paliperidone palmitate 3-month formulation (PP3M) is indicated in the United States for the treatment of schizophrenia only after adequate treatment with paliperidone palmitate 1-month formulation (PP1M) for ≥4 months. This analysis aimed to identi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuropsychiatr Dis Treat
Autores principales: Nash, Abigail I, Turkoz, Ibrahim, Savitz, Adam J, Mathews, Maju, Kim, Edward
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6435125/
https://ncbi.nlm.nih.gov/pubmed/30962688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S194264
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares